Literature DB >> 32162316

The effect of metformin on the risk of recurrent nonmelanoma skin cancers.

Adarsh Ravishankar1, Tianshun Zhang2, Bruce R Lindgren3, Ronda S Farah4, Zigang Dong2, Noah I Goldfarb5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32162316      PMCID： PMC7673232          DOI： 10.1111/ijd.14829

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  3 in total

1.  Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer.

Authors:  Daphne Reinau; Christian Surber; Susan S Jick; Christoph R Meier
Journal:  Int J Cancer       Date:  2014-12-03       Impact factor: 7.396

Review 2.  Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.

Authors:  Nisa M Maruthur; Eva Tseng; Susan Hutfless; Lisa M Wilson; Catalina Suarez-Cuervo; Zackary Berger; Yue Chu; Emmanuel Iyoha; Jodi B Segal; Shari Bolen
Journal:  Ann Intern Med       Date:  2016-04-19       Impact factor: 25.391

3.  Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes.

Authors:  Chin-Hsiao Tseng
Journal:  J Am Acad Dermatol       Date:  2017-12-13       Impact factor: 11.527
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.